B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells

Leukemia

Volumn 24, Issue 11, 2010, Pages 1885-1892

  Gross, E ^a   Lfaqihi Olive, F E ^b   Ysebaert, L ^a,c   Brassac, M ^a   Struski, S ^c   Kheirallah, S ^a   Fournie J J ^a   Laurent, G ^a,c   Quillet Mary, A ^a  

^a CHU PURPAN   (France)

^b IFR150 BMT   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

ABC transporters; B CLL; chemoresistance; side population

Indexed keywords

BENDAMUSTINE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL COMPARTMENTALIZATION; CELL HETEROGENEITY; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; HUMAN; INNATE IMMUNITY; MALE; PHENOTYPE; PRIORITY JOURNAL;

EID: 78149467760     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.176     Document Type: Article

References (38)

1. Montserrat E. Further progress in CLL therapy. Blood 2008; 112: 924-925.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017-1029.
3. Castro JE, Sandoval-Sus J, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22: 2048-2053.
4. Byrd JC, Lin TS, Grever MR. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin Oncol 2006; 33: 210-219.
5. Olsson A, Norberg M, Okvist A, Derkow K, Choudhury A, Tobin G et al. Upregulation of bfl-1 is a potential mechanism of chemo-resistance in B-cell chronic lymphocytic leukaemia. Br J Cancer 2007; 97: 769-777.
6. Pepper C, Hoy T, Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998; 28: 355-361.
7. Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M et al. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 1993; 85: 1751-1758.
8. Wulf GG, Wang RY, Kuehnle I, Preuss E, Huber C, Gotwald M et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173.
9. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833.
10. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251.
11. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human naso-pharyngeal carcinoma cell line. Cancer Res 2007; 67: 3716-3724.
12. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
13. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159.
14. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806.
15. Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco MM et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003; 5: R1-R8.
16. Meeson AP, Hawke TJ, Graham S, Jiang N, Elterman J, Hutcheson K et al. Cellular and molecular regulation of skeletal muscle side population cells. Stem Cells 2004; 22: 1305-1320.
17. Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol 2004; 265: 262-275.
18. Moserle L, Ghisi M, Amadori A, Indraccolo S. Side population and cancer stem cells: therapeutic implications. Cancer Lett 2009; 288: 1-9.
19. Triel C, Vestergaard ME, Bolund L, Jensen TG, Jensen UB. Side population cells in human and mouse epidermis lack stem cell characteristics. Exp Cell Res 2004; 295: 79-90.
20. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034.
21. Matsui W, Wang Q, Barber J, Brennan S, Smith BD, Borrello I et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197.
22. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E et al. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia 2010; 24: 563-572.
23. Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558-568.
24. Struski S, Gervais C, Helias C, Herbrecht R, Audhuy B, Mauvieux L. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia 2009; 23: 617-619.
25. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
26. Hadnagy A, Gaboury L, Beaulieu R, Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006; 312: 3701-3710.
27. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-260.
28. Bertrand FE, Eckfeldt CE, Fink JR, Lysholm AS, Pribyl JA, Shah N et al. Microenvironmental influences on human B-cell development. Immunol Rev 2000; 175: 175-186.
29. Damle RN, Ghiotto F, Valetto A, Yancopoulos S, Banapour T, Sison C et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110: 3352-3359.
30. Mainou-Fowler T, Dignum HM, Proctor SJ, Summerfield GP. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 2004; 45: 455-462.
31. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Iványi J, Schmitz G et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118-2128.
32. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008; 264: 549-562.
33. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008; 3: e3077.
34. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
35. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007; 104: 618-623.
36. de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008; 7: 3092-3102.
37. Prenkert M, Uggla B, Tina E, Tidefelt U, Strid H. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells. Anticancer Res 2009; 29: 4071-4076.
38. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology 2009; 14: 204-212.